For a patient population that is often heading toward total joint replacement, that outcome is genuinely practice-changing
To address this treatment gap, we engineered a proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing monoclonal antibody (mAb) fused to a glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonist peptide to deliver low-density lipoprotein cholesterol (LDL-C) lowering capabilities combined with glycaemic and weight control in a single molecule
B12 helps keep your blood cells healthy, while Vitamin C strengthens your immune system, a perfect match for staying resilient year-round
This comprehensive strategy provides clarity, confidence, and care in a GLP-1-influenced food environment
Retatrutide has already demonstrated impressive weight loss and encouraging improvements across multiple metabolic markers, making it one of the most closely watched investigational therapies in endocrinology
Federal regulators have approved a new diabetes drug that reduces blood-sugar levels and also helps people lose significant weight
